Table 2.
Count | % | P-Valueb | |
---|---|---|---|
KEGG Pathway | |||
Chemokine signaling pathway | 13 | 2.5 | 0.021 |
Endometrial cancer | 6 | 1.2 | 0.028 |
Melanoma | 7 | 1.4 | 0.03 |
Bladder cancer | 5 | 1 | 0.049 |
Cytokine-cytokine receptor interaction | 15 | 2.9 | 0.052 |
Thyroid cancer | 4 | 0.8 | 0.07 |
Jak-STAT signaling pathway | 10 | 1.9 | 0.072 |
Prostate cancer | 7 | 1.4 | 0.075 |
Pancreatic cancer | 6 | 1.2 | 0.09 |
Chronic myeloid leukemia | 6 | 1.2 | 0.1 |
GO Biological Process (level 5) | |||
regulation of apoptosis | 39 | 7.6 | 0.003 |
regulation of programmed cell death | 39 | 7.6 | 0.0036 |
catechol catabolic process | 3 | 0.6 | 0.0083 |
telomere maintenance | 5 | 1 | 0.0089 |
positive regulation of T cell mediated cytotoxicity | 3 | 0.6 | 0.017 |
positive regulation of apoptosis | 22 | 4.3 | 0.018 |
positive regulation of programmed cell death | 22 | 4.3 | 0.019 |
positive regulation of cell death | 22 | 4.3 | 0.02 |
positive regulation of hormone secretion | 5 | 1 | 0.021 |
nucleic acid transport | 8 | 1.6 | 0.025 |
aThe 29 Bonferroni-significant, gastric cancer-associated DMPs recovered by SmartSVA were used as an input to DAVID Functional Annotation Bioinformatics Microarray Analysis (https://david.ncifcrf.gov/)
bA modified Fisher Exact P-Value based on EASE Score for gene-enrichment analysis (https://david.ncifcrf.gov/). Usually P-Value equal or smaller than 0.05 is to be considered strongly enriched in the annotation categories